Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

• P. Jiménez-Fonseca ^[1] ; J. M. Gómez Saez ^[7] ; J. Santamaria Sandi ^[8] ; J. Capdevila ^[9] ; E. Navarro Gonzalez ^[2] ; C. Zafon Llopis ^[9] ; T. Ramón y Cajal Asensio ^[3] ; G. Riesco-Eizaguirre ^[4] ; E. Grande ^[5] ; J. C. Galofré ^[6]
  1. [1] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  2. [2] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  3. [3] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  4. [4] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  5. [5] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  6. [6] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  7. [7] Hospital Universitario de Bellvitge, España
  8. [8] Hospital Universitario de Cruces, España
  9. [9] Hospital Universitario de la Vall d’Hebron, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 1 (January 2017), 2017, págs. 12-20
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Anaplastic thyroid cancer (ATC) is the most aggressive solid tumor and almost uniformly lethal in humans. The Boards of the Thyroid Cancer Group of the Spanish Society of Endocrinology and Nutrition and the Grupo Español de Enfermedades Huérfanas e Infrecuentes of the Spanish Society of Oncology requested that an independent task force draft a more comprehensive consensus statement regarding ATC. All relevant literature was reviewed, including serial PubMed searches together with additional articles. This is the first, comprehensive Spanish consensus statement for ATC and includes the characteristics, diagnosis, initial evaluation, treatment goals, recommendations and modalities for locoregional and advanced disease, palliative care options, surveillance, and long-term monitoring. Newer systemic therapies are being investigated, but more effective combinations are needed to improve patient outcomes. Though more aggressive radiotherapy has reduced locoregional recurrences, median overall survival has not improved in more than 50 years.